Physician profile
Vincent Yang
NPI 1356513063
$3,575.84
in general payments reported to CMS, 2019-2025
17 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $62.96 · 2021: $117 · 2022: $220 · 2023: $36.89 · 2024: $2,579 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,550 · Food and Beverage: $344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,550.00 |
| Food and Beverage | $344.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $2,565.37 | 2021-2024 | Vafseo |
| Acist Medical Systems, INC. | $151.06 | 2019 | |
| Mallinckrodt Hospital Products INC. | $129.28 | 2025 | Terlivaz |
| Vantive US Healthcare LLC | $125.02 | 2025 | Renal - Pd |
| Bard Peripheral Vascular, INC. | $115.79 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $115.14 | 2019-2022 | |
| Nxstage Medical, INC. | $98.27 | 2022 | |
| Glaxosmithkline, LLC. | $55.62 | 2021-2023 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $49.49 | 2020 | |
| Amgen INC. | $34.91 | 2021 | |
| Vifor Pharma, INC. | $29.38 | 2022 | |
| Aurinia Pharma U.S., INC. | $28.69 | 2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $24.42 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.25 | 2023 | |
| Fresenius USA Marketing, INC. | $15.76 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $15.39 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.